-
16 December 2019: OIA response: Lamotrigine NPPA change
-
11 December 2019: OIA response: MMR vaccine stock
-
10 December 2019: OIA response: Antifungals data
-
10 December 2018: OIA response: 2018-12-12 Research projects
-
12 December 2019: OIA response: Adalimumab data
-
9 December 2019: OIA response: Lamotrigine brand change
-
5 December 2019: OIA response: Sildenafil
-
4 December 2019: OIA response: Statins prices
-
4 December 2019: OIA response: Lamotrigine NPPA data
-
28 November 2019: OIA response: Lamotrigine contingency plan activation
-
28 November 2019: OIA response: Male sex change hormones data
-
27 November 2019: OIA response: Asthma inhalers data
-
26 November 2019: OIA response: Fingolimod data
-
25 November 2019: OIA response: Pembrolizumab and nivolumab
-
25 November 2019: OIA response: Funded mental health drugs
-
21 November 2019: OIA response: Cefuroxime data
-
20 November 2019: OIA response: Pembrolizumab and nivolumab data, July to September 2019
-
19 November 2019: OIA response: Meningitis vaccines communications
-
14 November 2019: OIA response: Prescription numbers
-
12 November 2019: OIA response on MMR vaccine
-
31 October 2019: OIA Response: 2019-20 budget bid letter
-
29 October 2019: OIA response: Venlafaxine and lamotrigine NPPA data
-
24 October 2019: OIA response: Chloramphenicol data
-
24 October 2019: OIA response: Anti-VEGF treatment
-
24 October 2019: OIA response: Compassionate supply response
-
16 October 2019: Asthma inhalers
-
15 October 2019: OIA Response: Opioid substitution
-
1 October 2019: OIA response: Lamotrigine safety
-
26 September 2019: OIA response: Growth hormone data
-
25 September 2019: OIA response: Venlafaxine brand use data
-
18 September 2019: OIA response: Phenelzine supply
-
17 September 2019: OIA response: Leuprorelin and goserelin data
-
12 September 2019: OIA response: Psychometric testing
-
1 August 2019: OIA response: Pembrolizumab and nivolumab data
-
22 July 2019: OIA Response: Pfizer PHARMAC communications
-
19 July 2019: OIA Response: Asthma and Respiratory Foundation payments
-
16 July 2019: OIA Response: University of Auckland communications
-
5 July 2019: OIA Response: Keith Petrie communications
-
26 June 2019: OIA Response: Venlafaxine brand change data
-
20 June 2019: OIA Response: Meningococcal vaccine meetings
-
18 June 2019: OIA Response: Infliximab hospital purchase data
-
18 June 2019: OIA Response: Adalimumab and etanercept data
-
11 June 2019: OIA Response: MSTAC Minutes
-
11 June 2019: OIA Response: Adalimumab, etanercept, infliximab and secukinumab data
-
10 June 2019: OIA Response: Mesalazine data
-
10 June 2019: OIA Response: Compounding data for antiepileptics
-
30 May 2019: OIA Response: Pharmaceutical budget bid and final budgets
-
29 May 2019: OIA Response: Insulin needles and syringes data
-
23 May 2019: OIA Response: Pharmaceutical budget bid
-
22 May 2019: OIA Response: Pertuzumab renewals data
-
20 May 2019: OIA Response: Venlafaxine brand change roll out plan
-
15 May 2019: OIA Response: Lamotrigine correspondence
-
15 May 2019: OIA Response: Meningococcal W and Scout Jamboree
-
13 May 2019: OIA Response: Pembrolizumab criteria
-
9 May 2019: OIA Response: Vaccine costs
-
30 April 2019: OIA Response: Daivobet gel dispensing data
-
26 April 2019: OIA Response: PrEP Data
-
24 April 2019: OIA Response: Parental leave policies
-
16 April 2019: OIA Response: Antiepileptic medicines data
-
15 April 2019: OIA Response: Adrenaline autoinjector cost utility analysis
-
8 April 2019: OIA response: Sleeping medicines data
-
01 April 2019: OIA Response: Erlotinib and other medicines data
-
13 March 2019: OIA Response: Summary of factors determining CPB expenditure
-
27 February 2019: OIA Response: Pembrolizumab and nivolumab data
-
26 February 2019: OIA Response: Drug shortages
-
8 February 2019: OIA Response: Waitangi Tribunal research report
-
29 January 2019: OIA Response: Zytiga data
-
14 January 2019: OIA response: Technology Assessment Reports for pembrolizumab in advanced melanoma